GR3034293T3 - Rapamycin formulation for iv injection. - Google Patents
Rapamycin formulation for iv injection.Info
- Publication number
- GR3034293T3 GR3034293T3 GR20000401980T GR20000401980T GR3034293T3 GR 3034293 T3 GR3034293 T3 GR 3034293T3 GR 20000401980 T GR20000401980 T GR 20000401980T GR 20000401980 T GR20000401980 T GR 20000401980T GR 3034293 T3 GR3034293 T3 GR 3034293T3
- Authority
- GR
- Greece
- Prior art keywords
- rapamycin
- solution
- weight percent
- polyethylene glycol
- percent
- Prior art date
Links
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 title abstract 9
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 title abstract 9
- 229960002930 sirolimus Drugs 0.000 title abstract 9
- 238000009472 formulation Methods 0.000 title 1
- 238000002347 injection Methods 0.000 title 1
- 239000007924 injection Substances 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 229940068886 polyethylene glycol 300 Drugs 0.000 abstract 3
- 229920000136 polysorbate Polymers 0.000 abstract 3
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 abstract 2
- 229940113115 polyethylene glycol 200 Drugs 0.000 abstract 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract 2
- 239000002202 Polyethylene glycol Substances 0.000 abstract 1
- 239000012141 concentrate Substances 0.000 abstract 1
- 239000003085 diluting agent Substances 0.000 abstract 1
- 229940102223 injectable solution Drugs 0.000 abstract 1
- 229920001223 polyethylene glycol Polymers 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/7036—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin having at least one amino group directly attached to the carbocyclic ring, e.g. streptomycin, gentamycin, amikacin, validamycin, fortimicins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Dermatology (AREA)
- Biochemistry (AREA)
- Transplantation (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US86053092A | 1992-03-30 | 1992-03-30 | |
| PCT/US1993/002907 WO1993019763A1 (en) | 1992-03-30 | 1993-03-29 | Rapamycin formulation for iv injection |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| GR3034293T3 true GR3034293T3 (en) | 2000-12-29 |
Family
ID=25333426
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| GR20000401980T GR3034293T3 (en) | 1992-03-30 | 2000-08-31 | Rapamycin formulation for iv injection. |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US5530006A (el) |
| EP (1) | EP0633783B1 (el) |
| JP (1) | JPH07505628A (el) |
| KR (1) | KR950700750A (el) |
| AT (1) | ATE193652T1 (el) |
| AU (1) | AU681579B2 (el) |
| CA (1) | CA2132636C (el) |
| DE (1) | DE69328829T2 (el) |
| DK (1) | DK0633783T3 (el) |
| ES (1) | ES2148224T3 (el) |
| GR (1) | GR3034293T3 (el) |
| HU (2) | HUT70947A (el) |
| LV (1) | LV12657B (el) |
| MX (1) | MX9301740A (el) |
| NZ (1) | NZ251628A (el) |
| PH (1) | PH30923A (el) |
| PT (1) | PT633783E (el) |
| SG (1) | SG49652A1 (el) |
| TW (1) | TW427903B (el) |
| WO (1) | WO1993019763A1 (el) |
| ZA (1) | ZA932224B (el) |
Families Citing this family (60)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL111003A0 (en) * | 1993-09-30 | 1994-11-28 | American Home Prod | Multi-component oral rapamycin formulation |
| US5616588A (en) * | 1993-09-30 | 1997-04-01 | American Home Products Corporation | Rapamycin formulation for IV injection |
| US5527907A (en) * | 1993-11-19 | 1996-06-18 | Abbott Laboratories | Macrolide immunomodulators |
| JP4105761B2 (ja) * | 1993-11-19 | 2008-06-25 | アボット・ラボラトリーズ | ラパミシン（マクロライド）の半合成類似体免疫調節剤 |
| BE1009856A5 (fr) | 1995-07-14 | 1997-10-07 | Sandoz Sa | Composition pharmaceutique sous la forme d'une dispersion solide comprenant un macrolide et un vehicule. |
| US5780462A (en) * | 1995-12-27 | 1998-07-14 | American Home Products Corporation | Water soluble rapamycin esters |
| DE69627992T2 (de) * | 1996-01-08 | 2004-05-19 | Kabushiki Kaisha Toshiba, Kawasaki | Informationsaufzeichnungsmedium, aufzeichnungsverfahren und wiedergabegerät |
| US5989591A (en) * | 1997-03-14 | 1999-11-23 | American Home Products Corporation | Rapamycin formulations for oral administration |
| US5985325A (en) * | 1997-06-13 | 1999-11-16 | American Home Products Corporation | Rapamycin formulations for oral administration |
| US6682758B1 (en) | 1998-12-22 | 2004-01-27 | The United States Of America As Represented By The Department Of Health And Human Services | Water-insoluble drug delivery system |
| AU2001249182A1 (en) * | 2000-03-14 | 2001-09-24 | Genetics Institute Inc. | Use of rapamycin and agents that inhibit b7 activity in immunomodulation |
| WO2001068134A2 (en) * | 2000-03-14 | 2001-09-20 | Genetics Institute, Inc. | Therapies that improve graft survival, using antibodies against a b7 antigen |
| US6670355B2 (en) * | 2000-06-16 | 2003-12-30 | Wyeth | Method of treating cardiovascular disease |
| DK1319008T3 (da) | 2000-09-19 | 2009-02-09 | Wyeth Corp | Vandoplöselige rapamycinestere |
| US6399625B1 (en) | 2000-09-27 | 2002-06-04 | Wyeth | 1-oxorapamycins |
| US6399626B1 (en) | 2000-10-02 | 2002-06-04 | Wyeth | Hydroxyesters of 7-desmethylrapamycin |
| US6440991B1 (en) | 2000-10-02 | 2002-08-27 | Wyeth | Ethers of 7-desmethlrapamycin |
| ES2485841T3 (es) | 2002-02-01 | 2014-08-14 | Ariad Pharmaceuticals, Inc | Compuestos que contienen fósforo y usos de los mismos |
| DE60319118T2 (de) * | 2002-07-30 | 2009-02-05 | Wyeth | Parenterale formulierungen mit einem rapamycin hydroxyester |
| SI1539157T1 (sl) | 2002-09-18 | 2013-11-29 | Trustees Of The University Of Pennsylvania | Rapamicin za uporabo pri inhibiciji ali preprečevanju horoidalne neovaskularizacije |
| WO2005027906A1 (en) | 2003-09-18 | 2005-03-31 | Macusight, Inc. | Transscleral delivery |
| FR2862872A1 (fr) * | 2003-12-02 | 2005-06-03 | Palbian Snc | Composition a l'etat aqueux pour l'application perfusable d'un principe actif, notamment pharmacologique tel que le paracetamol. |
| US20050220835A1 (en) * | 2004-03-30 | 2005-10-06 | Jayaraman Ramesh B | Agent eluting bioimplantable devices and polymer systems for their preparation |
| US8003122B2 (en) | 2004-03-31 | 2011-08-23 | Cordis Corporation | Device for local and/or regional delivery employing liquid formulations of therapeutic agents |
| US7846940B2 (en) * | 2004-03-31 | 2010-12-07 | Cordis Corporation | Solution formulations of sirolimus and its analogs for CAD treatment |
| EP1768662A2 (en) | 2004-06-24 | 2007-04-04 | Novartis Vaccines and Diagnostics, Inc. | Small molecule immunopotentiators and assays for their detection |
| US20060182771A1 (en) | 2005-02-09 | 2006-08-17 | Dor Philippe J | Formulations for ocular treatment |
| US8663639B2 (en) * | 2005-02-09 | 2014-03-04 | Santen Pharmaceutical Co., Ltd. | Formulations for treating ocular diseases and conditions |
| JP2008535858A (ja) * | 2005-04-07 | 2008-09-04 | ニトロメッド インコーポレーティッド | 心不全における遺伝リスク、すなわちｎｏｓ３の遺伝子変異の影響の評価方法 |
| WO2007041681A2 (en) * | 2005-10-04 | 2007-04-12 | Nitromed, Inc. | Methods for treating respiratory disorders |
| EP1945030A4 (en) * | 2005-10-04 | 2009-10-21 | Nitromed Inc | GENETIC RISK ASSESSMENT FOR HEART FAILURE: INFLUENCE OF GENETIC VARIATION ON GLY389ARG POLYMORPHISM OF THE BETA 1 ADRENERGENIC RECEPTOR |
| EP2001438A2 (en) | 2006-02-09 | 2008-12-17 | Macusight, Inc. | Stable formulations, and methods of their preparation and use |
| CA2634473A1 (en) * | 2006-02-17 | 2007-08-30 | Nitromed, Inc. | Methods using hydralazine compounds and isosorbide dinitrate or isosorbide mononitrate |
| DK2001466T3 (en) | 2006-03-23 | 2016-02-29 | Santen Pharmaceutical Co Ltd | LOW-DOSAGE RAPAMYCINE FOR TREATMENT OF VASCULAR PERMEABILITY-RELATED DISEASES |
| AU2007238949A1 (en) * | 2006-04-10 | 2007-10-25 | Nitromed, Inc, | The genetic risk assessment in heart failure: impact of the genetic variation of G-protein beta 3 subunit polymorphism |
| EP1938800A1 (en) | 2006-12-06 | 2008-07-02 | Ranbaxy Laboratories Limited | Sirolimus nanodispersion |
| WO2008083169A2 (en) * | 2006-12-26 | 2008-07-10 | The Johns Hopkins University | Compositions and methods for the treatment of immunologic disorders |
| JP5481199B2 (ja) * | 2006-12-27 | 2014-04-23 | ザ ジョンズ ホプキンス ユニバーシティー | 炎症および自己免疫疾患を治療するための組成物および方法 |
| US7989173B2 (en) | 2006-12-27 | 2011-08-02 | The Johns Hopkins University | Detection and diagnosis of inflammatory disorders |
| US20080265343A1 (en) * | 2007-04-26 | 2008-10-30 | International Business Machines Corporation | Field effect transistor with inverted t shaped gate electrode and methods for fabrication thereof |
| US8409601B2 (en) | 2008-03-31 | 2013-04-02 | Cordis Corporation | Rapamycin coated expandable devices |
| US8420110B2 (en) | 2008-03-31 | 2013-04-16 | Cordis Corporation | Drug coated expandable devices |
| US20100098770A1 (en) * | 2008-10-16 | 2010-04-22 | Manikandan Ramalingam | Sirolimus pharmaceutical formulations |
| CA2772199A1 (en) | 2009-08-31 | 2011-03-03 | Amplimmune, Inc. | B7-h4 fusion proteins and methods of use thereof |
| KR101267813B1 (ko) * | 2009-12-30 | 2013-06-04 | 주식회사 삼양바이오팜 | 향상된 수용해도를 갖는 라파마이신 함유 고분자나노입자 주사제형 조성물 및 그 제조방법, 및 방사선 요법과 병용하기 위한 항암 조성물 |
| US9101541B2 (en) | 2010-04-28 | 2015-08-11 | Cadila Healthcare Limited | Stable solid pharmaceutical matrix compositions of sirolimus |
| WO2012092421A2 (en) * | 2010-12-30 | 2012-07-05 | Surmodics, Inc. | Composition for intravascular delivery of therapeutic composition |
| PL2836234T3 (pl) | 2012-04-12 | 2020-02-28 | Yale University | Podłoża do kontrolowanego dostarczania różnych środków farmaceutycznych |
| CA2894689A1 (en) | 2012-12-19 | 2014-06-26 | Amplimmune, Inc. | Anti-human b7-h4 antibodies and their uses |
| WO2014186798A1 (en) | 2013-05-17 | 2014-11-20 | Amplimmune, Inc. | Receptors for b7-h4 |
| US10603325B2 (en) | 2014-10-29 | 2020-03-31 | University Of Maryland | Methods of treating age-related symptoms in mammals and compositions therefor |
| WO2017041053A1 (en) | 2015-09-04 | 2017-03-09 | Yale University | Polymeric bile acid nanocompositions targeting the pancreas and colon |
| US20190117799A1 (en) | 2016-04-01 | 2019-04-25 | The Brigham And Women's Hospital, Inc. | Stimuli-responsive nanoparticles for biomedical applications |
| CN109789197A (zh) | 2016-08-03 | 2019-05-21 | 奈斯科尔公司 | 用于调节lair信号转导的组合物和方法 |
| EP4360714A3 (en) | 2016-09-21 | 2024-07-24 | Nextcure, Inc. | Antibodies for siglec-15 and methods of use thereof |
| KR102644544B1 (ko) | 2016-09-21 | 2024-03-11 | 넥스트큐어 인코포레이티드 | Siglec-15를 위한 항체 및 이의 사용 방법 |
| WO2019217661A1 (en) | 2018-05-09 | 2019-11-14 | Yale University | Compositions and systems for ex vivo cell modulation and methods of use thereof |
| EP3790592A1 (en) | 2018-05-09 | 2021-03-17 | Yale University | Particles for spatiotemporal release of agents |
| CA3123886A1 (en) | 2019-01-17 | 2020-07-23 | James DAHLMAN | Drug delivery systems containing oxidized cholesterols |
| WO2021258042A1 (en) | 2020-06-19 | 2021-12-23 | Yale University | Polymeric bile acid ester nanoparticles comprising an immunomodulator agent to induce antigen-specific tolerance |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3627886A (en) * | 1968-04-15 | 1971-12-14 | Hoffmann La Roche | Methods of solubilizing coumermycin employing urea, dimethylacetamide or mixtures thereof |
| ZA737247B (en) * | 1972-09-29 | 1975-04-30 | Ayerst Mckenna & Harrison | Rapamycin and process of preparation |
| AU543727B2 (en) * | 1980-06-02 | 1985-05-02 | Ayerst Mckenna & Harrison Inc. | Injectable composition of rapamycin |
| US4707470A (en) * | 1985-05-17 | 1987-11-17 | Smithkline Beckman Corporation | Polyene antibiotic emulsion formulation |
| US5202241A (en) * | 1988-09-09 | 1993-04-13 | Gruppo Lepetit S.P.A. | Antibiotic GE 2270 |
| KR0177158B1 (ko) * | 1990-03-01 | 1999-03-20 | 후지사와 도모기찌로 | 면역억제 활성을 갖는 트리사이클릭 화합물 함유 용액 제제 |
-
1993
- 1993-03-29 EP EP93908637A patent/EP0633783B1/en not_active Expired - Lifetime
- 1993-03-29 ES ES93908637T patent/ES2148224T3/es not_active Expired - Lifetime
- 1993-03-29 CA CA002132636A patent/CA2132636C/en not_active Expired - Fee Related
- 1993-03-29 DK DK93908637T patent/DK0633783T3/da active
- 1993-03-29 AU AU39391/93A patent/AU681579B2/en not_active Ceased
- 1993-03-29 HU HU9402821A patent/HUT70947A/hu unknown
- 1993-03-29 MX MX9301740A patent/MX9301740A/es not_active IP Right Cessation
- 1993-03-29 ZA ZA932224A patent/ZA932224B/xx unknown
- 1993-03-29 NZ NZ251628A patent/NZ251628A/en unknown
- 1993-03-29 SG SG1996002833A patent/SG49652A1/en unknown
- 1993-03-29 AT AT93908637T patent/ATE193652T1/de not_active IP Right Cessation
- 1993-03-29 JP JP5517594A patent/JPH07505628A/ja active Pending
- 1993-03-29 PT PT93908637T patent/PT633783E/pt unknown
- 1993-03-29 PH PH45950A patent/PH30923A/en unknown
- 1993-03-29 DE DE69328829T patent/DE69328829T2/de not_active Expired - Fee Related
- 1993-03-29 WO PCT/US1993/002907 patent/WO1993019763A1/en not_active Ceased
- 1993-03-31 TW TW082102409A patent/TW427903B/zh not_active IP Right Cessation
-
1994
- 1994-03-07 US US08/207,325 patent/US5530006A/en not_active Expired - Lifetime
- 1994-09-28 KR KR1019940703368A patent/KR950700750A/ko not_active Withdrawn
-
1995
- 1995-06-28 HU HU95P/P00517P patent/HU211841A9/hu unknown
-
2000
- 2000-08-31 GR GR20000401980T patent/GR3034293T3/el not_active IP Right Cessation
-
2001
- 2001-03-06 LV LV010033A patent/LV12657B/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| PH30923A (en) | 1997-12-23 |
| LV12657A (lv) | 2001-05-20 |
| AU681579B2 (en) | 1997-09-04 |
| CA2132636A1 (en) | 1993-10-14 |
| HU9402821D0 (en) | 1994-12-28 |
| SG49652A1 (en) | 1998-06-15 |
| CA2132636C (en) | 2002-12-17 |
| LV12657B (lv) | 2001-09-20 |
| PT633783E (pt) | 2000-11-30 |
| EP0633783B1 (en) | 2000-06-07 |
| KR950700750A (ko) | 1995-02-20 |
| ATE193652T1 (de) | 2000-06-15 |
| AU3939193A (en) | 1993-11-08 |
| US5530006A (en) | 1996-06-25 |
| ZA932224B (en) | 1994-09-29 |
| TW427903B (en) | 2001-04-01 |
| HUT70947A (en) | 1995-11-28 |
| DE69328829T2 (de) | 2000-10-12 |
| ES2148224T3 (es) | 2000-10-16 |
| NZ251628A (en) | 1996-07-26 |
| JPH07505628A (ja) | 1995-06-22 |
| MX9301740A (es) | 1993-09-01 |
| HU211841A9 (en) | 1995-12-28 |
| DK0633783T3 (da) | 2000-09-25 |
| WO1993019763A1 (en) | 1993-10-14 |
| EP0633783A1 (en) | 1995-01-18 |
| DE69328829D1 (de) | 2000-07-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| GR3034293T3 (en) | Rapamycin formulation for iv injection. | |
| HU9402809D0 (en) | Rapamycin formulation for iv injection | |
| HU9402808D0 (en) | Rapamycin formulation for iv injection | |
| AU4478093A (en) | PEG-interferon conjugates | |
| HU9501767D0 (en) | Aqueous pharmaceutical preparations of g-csf with a long shelf life | |
| ES2045028T3 (es) | Esteres de acidos carboxilicos biologicamente activos. | |
| PE20000018A1 (es) | Composiciones farmaceuticas a base de dalfopristina y de quinupristina y su preparacion | |
| ES2151255T3 (es) | Poliaminoacido para fomentar la absorcion de insecticida. | |
| ATE416790T1 (de) | Wasserlösliche trockene zusammensetzungen | |
| IL104854A0 (en) | Dioxolane derivatives | |
| JPS6471439A (en) | Freshness retaining agent for fishes and shellfishes | |
| Tarnok et al. | Interaction of cimetidine and histamine with superoxide generated in a cell-free system and in neutrophils | |
| AU4872893A (en) | Antithrombin III preparation | |
| KR900000081A (ko) | 트리암테렌의 약학적 액제 | |
| JPS6425720A (en) | Percutaneous absorption pharmaceutical |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| ML | Lapse due to non-payment of fees |